2. References:
Anticoagulation should be continued 3-6 months for the treatment of VTE in cancer patients:
1. ASCO: Lyman GH, Bohlke K, Khorana AA, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients with Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update J Clin Oncol 2015; 33(6):
2. ESMO: Mandalà M, Falanga A, Roila F. Management of Venous Thromboembolism (VTE) in Cancer Patients: ESMO Clinical Practice Guidelines. Ann Oncol 2011; 22 (Suppl 6): vi85-vi92.
3. NCCN: Streiff MB, Holmstrom B, Bockenstedt PL, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™). Cancer-Associated Venous Thromboembolic Disease, Version 1, 2017.
4. ISTH: Farge D, Debourdeau P, Beckers M, et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Journal of Thrombosis and Haemostasis Jan 1;11(1):56-70.
5. ACCP: Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest 2016; 149(2):